• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Triple Analysis: Apoptosis, Cancer Vaccines and Peptides Product Image

Triple Analysis: Apoptosis, Cancer Vaccines and Peptides

  • Published: March 2013
  • Region: Global
  • 3637 pages
  • Bioseeker

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined READ MORE >

Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of
Pages: 1,617

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of
Pages: 1,007

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of
Pages: 1,013

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos